RCS - Rair Health Limited - RAIR announces the launch of RAIR Knowledge Graph

Green Cross HealthAnnouncement

11/05/2021 10:05

RNS Number : 1426Y
  
Rair Health Limited
  
11 May 2021
  
 

 
May 11, 2021
RAIR HEALTH LIMITED
("RAIR" or "the Company")
 
RAIR Health announces the launch of RAIR Knowledge Graph, the first knowledge engineering tool dedicated to ophthalmic research and development.
 
RAIR Health Limited, a digital contract research organisation focused on the generation of proprietary insights from ophthalmic data and images, announces the launch of RAIR Knowledge Graph ("RKG"), connecting human proteins, genes, pathways, SNPs and drugs, related to ophthalmic diseases. RAIR's new data science tool gives researchers an unparalleled opportunity to use state-of-the-art AI to discover, interact and draw insight from a vast store of structured and unstructured life science knowledge. 
 
RAIR Knowledge Graph
 
RKG comprises a hyperlinked graph database of over 1.4 million entities and tens of millions of relationships, curated from diseases that manifest in the eye. Indications covered by the database include macular degeneration, glaucoma, Alzheimer's disease, chronic kidney disease, rheumatological disease and cardiovascular diseases. RKG semantically connects public-domain databases with research abstracts to find hidden relationships between widely disparate data. This multi-omic, big-data tool can help to generate hypotheses for drug development or repurposing; biomarkers for early diagnosis; and to illuminate novel or improved treatment pathways.
 
Knowledge Graphs -- Powerful Big-Data Technology
 
The graph technology that underlies RKG, allows semantically-rich databases to be integrated in a conceptual and flexible way. RKG has an in-built automated, deductive reasoning engine that does not require labour-intensive feature engineering. And rather than being a black box, RKG is able to fully explain its reasoning, thus providing results that are traceable and understandable. 
 
Relational data models are often constrained because they store information as "strings" in row/column relationships, making them unsuitable for modelling complex knowledge domains. RKG's data model solves this by storing information as "concepts" and allowing n-relational connections. This hyper-relational schema gives RKG the ability to understand complex queries and provide powerful insights as results. 
 
Together these make RKG the perfect tool for product/service ideation and the formation of hypotheses for the purposes of AI-enabled development.
 
Steve Cox, CEO of RAIR Health, said: "We are excited that RKG can provide our collaborators with a new way of investigating novel relationships between proteins, genes, drugs and diseases. RKG enables us to abstract complex biomedical concepts and to visualise them in ways that reveal insights that might otherwise take years to replicate. With return on research investment at a low, we believe AI tools like this can contribute to the reinvigoration of research productivity."
 
RKG is part of RAIR's Oculair suite of products for researchers in ophthalmic and related diseases. Additional Oculair solutions will provide end-to-end resources for researchers using bioinformatics and machine learning to develop new products and services, based on proprietary real-world clinical data.
 
For further information, please contact:
 
RAIR Health Limited
Steve Cox
Tel: + 44 (0) 20 7924 2345
Chief Executive Officer
 
About RAIR Health Limited: RAIR is a data-driven digital contract research organisation. It is focused on the provision of solutions related to the application of artificial intelligence in the development of digital health products and the provision of data to meet the growing demand for digital information to support the development pathway. RAIR is focused on chronic diseases that manifest in the eye, which aside from ophthalmology, include large therapeutic areas like cardiovascular, rheumatological and neurological disease.
 
Please visit www.rair.ai

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRAGPUACAUPGGQU